BLT.AX - Benitec Biopharma Limited

ASX - ASX Delayed Price. Currency in AUD
0.20
+0.01 (+2.56%)
At close: 3:43PM AEDT
Stock chart is not supported by your current browser
Previous Close0.19
Open0.20
Bid0.19 x 9834400
Ask0.20 x 752800
Day's Range0.19 - 0.20
52 Week Range0.09 - 0.28
Volume196,634
Avg. Volume266,014
Market Cap41.029M
BetaN/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • TheStreet.com14 days ago

    Alkermes Jumps on License Deal With Biogen -- Biotech Movers

    Alkermes and Biogen have inked a pact to develop and commercialize ALKS 8700, which is in Phase 3 development for treating relapsing forms of multiple sclerosis.

  • Reuterslast month

    LMEWEEK-Electric cars set world's nickel miners on new course

    SYDNEY/MELBOURNE, Oct 31 (Reuters) - Battery makers are increasingly turning to nickel to help power growing global electric car sales, but only half of the world's producers of the metal are likely to benefit, mining analysts and executives say. Lithium batteries containing nickel, which helps keep a charge over longer distances, are being installed in electric cars from Tesla's top-of-the-line Model X to General Motors Co modestly-priced Chevy Bolt. The battery boom promises a new and growing market for miners producing high-grade nickel products.

  • Rising Biotechs: Paratek Among Stocks Surging On Trial Results
    Investor's Business Daily8 months ago

    Rising Biotechs: Paratek Among Stocks Surging On Trial Results

    Paratek, Cyclacel and Benitec stocks led a biotech surge on Tuesday, rising on strong trial results.

  • Here's Why Benitec Biopharma Stock Soared 79.7% Higher This Morning
    Motley Fool8 months ago

    Here's Why Benitec Biopharma Stock Soared 79.7% Higher This Morning

    The company announced preclinical data supporting its gene replacement therapy in a rare muscle disease.

  • 24/7 Wall St.10 months ago

    Why Benitec More Than Doubled

    Benitec Biopharma saw its shares more than double on Tuesday after the company gave a business update on its ddRNAi technology for the development of therapeutics for the treatment of ocular diseases.

  • Benitec Stock Up on Orphan Drug Status for BB-301 in EU
    Zacks11 months ago

    Benitec Stock Up on Orphan Drug Status for BB-301 in EU

    Benitec (BNTC) announced that its proposed candidate, BB-301, received Orphan Drug Designation in the EU for the treatment of ocularpharyngeal muscular dystrophy.

  • 24/7 Wall St.11 months ago

    Tuesday’s Top Biopharma Movers

    A few biotech and pharma companies were on the move Tuesday. A few of the smaller caps made tremendous gains on the day, as the fourth-quarter earnings season is kicking off.